SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August
1, 2018
DTHERA
SCIENCES
(Exact Name of Registrant as Specified in
Charter)
|
Nevada
|
333-191175
|
90-0925768
|
|
(State or Other Jurisdiction of Incorporation)
|
Commission File Number
|
(IRS Employer Identification No.)
|
|
7310 Miramar Rd Suite 350., San Diego, CA
|
92126
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(858)
215-6360
______________________________________________
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
|
Item 7.01
|
Regulation FD Disclosure.
|
Press Release – Launch of ReminX
TM
Dthera Sciences, a Nevada corporation (the “Company”),
announced on August 1, 2018, the launch of ReminX™, an artificial-intelligence-powered consumer health product designed to
digitally deliver Reminiscence Therapy to individuals suffering from Alzheimer's and other dementias, as well as from social isolation.
This digital therapeutic device is the first to focus on the care of the elderly.
According to the Alzheimer's Association, Alzheimer's disease
is the only top 10 cause of death that cannot be prevented, cured, or slowed. Additionally, nearly half of elderly Americans are
estimated to be impacted by social isolation, and AARP estimates the health effects of social isolation to be equivalent to smoking
15 cigarettes per day.
The Company announced that ReminX seeks to digitize and scale
Reminiscence Therapy, a common behavioral intervention used to treat these conditions. ReminX features a computer tablet designed
specifically for seniors, as well as an AI chatbot that interacts with family members and caregivers via text messages or its mobile
app, prompting them to send a photo, voice narration, and video content regularly and optimizing the content into personalized
stories. ReminX also features proprietary emotional recognition software to further improve content for each user and to communicate
emotional responses back to the family.
The
press release included as Exhibit 99.1 will be deemed to be “furnished” rather than “filed,” pursuant to
the rules of the Securities and Exchange Commission
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Dthera Sciences
|
|
|
|
|
|
|
|
Date: August 6, 2018
|
|
|
|
By:
/s/ Edward Cox
|
|
|
Name: Edward Cox
|
|
|
Title: Chief Executive Officer
|
Exhibit 99.1
Dthera Sciences Launches ReminX -- The
First Digital Therapeutic Consumer Health Product for Individuals with Alzheimer’s Disease and Social Isolation
San Diego, CA (August 1, 2018)
-- Dthera™ Sciences
(OTCQB:DTHR), a San Diego-based digital therapeutics company developing innovative quality of life therapies for the elderly, announced
the launch of ReminX™, an artificial-intelligence-powered consumer health product designed to digitally deliver Reminiscence
Therapy to individuals suffering from Alzheimer’s and other dementias, as well as from social isolation. This digital therapeutic
device is the first to focus on the care of the elderly.
According to the Alzheimer’s Association, Alzheimer’s
disease is the only top 10 cause of death that cannot be prevented, cured, or slowed. Additionally, nearly half of elderly Americans
are estimated to be impacted by social isolation, and AARP estimates the health effects of social isolation to be equivalent to
smoking 15 cigarettes per day.
Launching today, ReminX seeks to digitize and scale Reminiscence
Therapy, a common behavioral intervention used to treat these conditions. ReminX features a computer tablet designed specifically
for seniors, as well as an AI chatbot that interacts with family members and caregivers via text messages or its mobile app, prompting
them to send photo, voice narration, and video content regularly and optimizing the content into personalized stories. ReminX also
features proprietary emotional recognition software to further improve content for each user and to communicate emotional responses
back to the family.
"The launch of ReminX represents the culmination of years
and technological and scientific development. I am very proud of our team for bringing a truly breakthrough and first-of-its-kind
digital therapeutic to what is probably the single largest unmet medical need of our lifetime – Alzheimer’s disease,"
said Edward Cox, CEO of Dthera Sciences. "For the first time, hyper-personal Reminiscence Therapy can be delivered to thousands
of individuals for a little over a dollar a day. This is a great example of compelling science and scalable technology being combined
to make a major positive impact."
In a clinical pilot study conducted through the University of
California, San Diego, ReminX was shown to significantly reduce anxiety, depression, and overall emotional distress in patients
with dementia. The study results were presented at the 40th Annual International Conference of the IEEE Engineering in Medicine
and Biology Society in July 2018.
“There is currently a great void in treating mood symptoms
often seen in patients with dementia,” said Vincent Filoteo, Ph.D., Section Chief of Neuropsychology and Professor of Psychiatry
at University of California, San Diego, and lead investigator in the study. “Reminiscence Therapy is a well-validated treatment
for these symptoms in both dementia and social isolation. A tool that can digitally deliver Reminiscence Therapy in a consistent
and highly accessible manner has the potential to have an even greater impact on mood symptoms, and would most likely also improve
cognition and quality of life.”
For more information, please visit
www.dthera.com
and
www.reminx.com.
About Reminiscence Therapy
Reminiscence Therapy is a behavioral intervention that helps
individuals with cognitive decline through the use of familiar pictures, music, voices, and other materials. It has been shown
in decades of clinical studies and in real-world use to help address behavioral symptoms of dementia. It was also shown to reduce
loneliness and depression in a recent systematic review of more than 400 clinical studies of social isolation. The benefits of
Reminiscence Therapy have long been recognized, however, it is labor intensive and difficult to deliver to large populations of
patients. ReminX seeks to replicate and improve upon Reminiscence Therapy and to make the intervention scalable for the first time.
About Dthera Sciences
Dthera Sciences (OTCQB:DTHR), based in San Diego, CA, is a digital
therapeutics company developing innovative quality of life therapies for the elderly and those suffering from cognitive decline.
The company’s lead product, ReminX™, is an artificial-intelligence-powered consumer health product designed to digitally
deliver Reminiscence Therapy to individuals suffering from neurodegenerative diseases such as Alzheimer’s disease and other
dementias, as well as social isolation.
Forward Looking Statement
This press release contains "forward-looking statements"
as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization
of therapeutic products and technologies; the efficacy of the ReminX technology; the scalability of the ReminX technology; and
the cost to deliver the ReminX technology, as well as the Company’s efforts to increase its customer base. Such forward-looking
statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay,
divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations.
No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release,
and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors
set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings
made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
# # #
CONTACTS
Company Contact
Geno Kostikov, Director, Dthera Corporate Development
geno@dthera.com
- (858) 215-6360
Media Relations
Joice Truban Curry, Publicist, c3 Communications, Inc.
joice@c3publicrelations.com - (619) 540-6611
Investor Relations
Marek Ciszewski, J.D., Managing Director, Head of Life Sciences,
Liolios
DTHR@Liolios.com - (949) 574-3860